Core Insights - Hydreight Technologies Inc. has reported significant growth, processing over 295,000 VSDHOne product orders from July to September 2025, indicating a robust expansion in its nurse network and a strong financial position with approximately CA$18.7 million in cash [1][6][9]. Company Performance - The company ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada for revenue growth from 2021 to 2024, and previously ranked 56 on Deloitte's 2024 Technology Fast 500™ in the U.S., highlighting its leadership in modernizing healthcare delivery through technology [3][6]. - Hydreight operates one of the largest compliant telehealth and medical networks in the U.S., connecting healthcare providers, pharmacies, and patients through its VSDHOne platform across all 50 states [4][13]. Recent Highlights - The company saw a 49% year-over-year increase in new nurse sign-ups, with 198 new sign-ups between July and September 2025 compared to 133 in the same period last year, and a total of 593 sign-ups in the first nine months of 2025, up from 364 in 2024 [9]. - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, reflecting sustained growth across multiple wellness verticals [9]. Financial Position - Hydreight enhanced its liquidity with an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing its cash position to approximately CA$18.7 million as of October 22, 2025 [9][12]. - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value while scaling its telehealth infrastructure nationally [12]. Strategic Initiatives - The company is actively integrating 503A/503B pharmacy partners to improve capacity, fulfillment speed, and margin potential, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9]. - Hydreight is expanding its GLP-1 program and direct-to-consumer wellness offerings, with ongoing national rollout initiatives [10][9]. Industry Recognition - Hydreight has been recognized as a Top 50 TSX Venture Exchange Company for 2024 and selected as a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8].

Core Insights - Hydreight Technologies Inc. has reported significant growth in product orders and nurse network expansion, with over 295,000 VSDHOne product orders processed between July and September 2025, indicating a strong demand for its services [1][9] - The company has a robust cash position of approximately CA$18.7 million, positioning it well for future growth initiatives [6][9] - Hydreight has received multiple recognitions for its rapid growth and innovation, including being ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada [3][8] Company Performance - The company processed ~295,000 VSDHOne product orders from July to September 2025, reflecting broad growth across various wellness verticals [9] - Nurse network expansion saw 198 new nurse sign-ups in Q3 2025, a 49% increase year-over-year, and a total of 593 sign-ups in the first nine months of 2025, up ~63% from 2024 [9] - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, indicating sustained growth and broader adoption [9] Financial Position - Hydreight's liquidity was enhanced by an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing cash reserves to approximately CA$18.7 million as of October 22, 2025 [9] - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value [12] Strategic Developments - Hydreight is actively integrating 503A/503B pharmacy partners to improve capacity and fulfillment speed, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9] - The company is rolling out Dr. Franklin Joseph's GLP-1 program nationally to meet increasing patient demand [10] - Hydreight is evaluating potential mergers and acquisitions of profitable multi-state wellness and digital health operators to scale nationally [9] Industry Recognition - Hydreight was recognized as a Top 50 TSX Venture Exchange Company for 2024 and was a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8] - The company has been acknowledged for its leadership in modernizing healthcare delivery through technology and compliance [3]

Group 1 - The company announced that at the 2025 Annual General Meeting (AGM) held on September 19, 2025, shareholders voted in favor of all items of business, and all director nominees were elected [1] - The company's fixed omnibus equity incentive plan was approved by a majority of shareholders, which includes unallocated securities that may be grantable under the plan [2] - The amended Equity Incentive Plan allows for up to 9,000,000 common shares to be issued from equity-based incentive awards granted to eligible persons, subject to final Exchange approval [3] Group 2 - Following the AGM, the company re-appointed Shane Madden as Chief Executive Officer, Joshua Sorin as Chief Financial Officer and Corporate Secretary, and Carey Dillen as Audit Committee Chair [4]

Core Insights - Hydreight Technologies Inc. has reported stronger-than-expected order growth and strategic advancements, indicating a robust performance in the mobile clinical network sector [1][2][3] Order Growth and Market Momentum - In August 2025, Hydreight processed over 80,000 pharmacy and telehealth product orders, exceeding the internal forecast of approximately 55,000 orders, reflecting broad demand across multiple service lines [2] - The company has seen an 86% year-over-year increase in pharmacy orders from January to August 2025, indicating significant market momentum [3] Strategic Growth Initiatives - Hydreight has invested in making the VSDHOne platform fully modular, enhancing customer adoption and expanding its total addressable market [4] - The company reported a 33% year-over-year revenue growth for H1 2025, marking its third consecutive quarter of profitability, driven by strong pharmacy order growth and network expansion [4] - An oversubscribed financing round raised $11.5 million to support strategic initiatives and strengthen the balance sheet [4] - The acquisition of a 5% stake in Perfect Scripts LLC aims to enhance operational control over pharmacy fulfillment and support margin expansion [4] AI Integration - Hydreight is in due diligence to acquire an AI-driven tool designed to provide personalized IV treatment recommendations, which is expected to enhance clinical decision-making and marketing capabilities [5] Customer Lifetime Value (LTV) Expansion - The company is focusing on expanding Customer Lifetime Value (LTV) by encouraging patients to engage with multiple service offerings within its ecosystem, thereby deepening patient relationships and improving unit economics [6] Outlook - Management emphasizes the need for continued investment in infrastructure, technology, and regulatory compliance to sustain growth, particularly in integrating new acquisitions [7] Competitive Position - Hydreight believes its established provider network, expanding pharmacy relationships, and growing patient demand position it favorably in the fragmented U.S. digital health market [8] Management Commentary - The CEO highlighted the broad-based adoption of Hydreight's services across various healthcare segments, indicating a strong platform performance [9] - The company is committed to building a scalable and compliant model that delivers value to patients, providers, and shareholders [10]

Core Viewpoint - Hydreight Technologies Inc. has successfully closed a private placement of unsecured convertible debentures, raising gross proceeds of C$11,500,000 to support its growth strategy and operational efficiency [1][4]. Group 1: Offering Details - The company issued a total of 11,500 convertible debentures at an issue price of C$1,000 each, including 1,500 debentures sold under the agent's over-allotment option [1]. - The debentures are unsecured, maturing on September 4, 2028, with an annual interest rate of 9.0%, payable semi-annually starting December 31, 2025 [2]. - Holders of the debentures can convert them into common shares at a conversion price of C$4.06 per share [2]. Group 2: Forced Conversion Right - The company has the option to force the conversion of the debentures if the volume-weighted average trading price of its common shares exceeds C$5.08 for 20 consecutive trading days [3]. - A notice will be provided to debenture holders if the forced conversion right is exercised, specifying the conversion date, which will be at least 30 days after the notice [3]. Group 3: Financial and Operational Insights - The CEO highlighted that the company has reached profitability as reflected in its Q2 financials and emphasized the importance of this funding for accelerating growth [4]. - The net proceeds from the offering will be utilized for general corporate and working capital purposes [5]. Group 4: Company Overview - Hydreight Technologies Inc. is developing a large mobile clinic network in the U.S., with a platform that connects over 2,500 nurses and 100 doctors across all 50 states [8]. - The platform includes integrated tools for healthcare professionals to provide services directly to patients, enhancing convenience and compliance [8].

Core Viewpoint - Hydreight Technologies Inc. has entered into a strategic partnership with Perfect Scripts LLC, which includes acquiring a 5% membership interest in Perfect Scripts and establishing a 503B pharmacy in the U.S. [1][2] Company Overview - Hydreight Technologies Inc. operates a fully integrated mobile clinical network in North America, comprising over 2,500 nurses and 100 doctors, along with a pharmacy network across all 50 states [13][14]. - Perfect Scripts LLC is the parent company of PerfectRx LLC and PerfectionRx LLC, which operate pharmacies and provide pharmaceutical services [6][9]. Transaction Details - Hydreight will acquire a 5% membership interest in Perfect Scripts for 2,250,000 common shares, with a deemed price of CAD$2.30 per share or the lowest price permitted by the TSX Venture Exchange [2]. - The partnership will allow Hydreight to receive the lowest pricing for products sold by Perfect Scripts and grants the right to maintain and increase its membership interest up to 40% [2][3]. Financial Aspects - A cash finder's fee of $258,750 will be paid to a finder in connection with the transaction, representing 5% of the deemed value [3]. - The Hydreight Compensation Shares will vest in increments and are subject to a four-month statutory hold period under Canadian securities laws [4][5]. Strategic Implications - The partnership is expected to enhance Hydreight's pharmacy margins, secure a consistent supply chain, and provide vertical integration, which will strengthen its market position [6][8]. - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight and Perfect Scripts [8]. Operational Capabilities - PerfectRx LLC operates a 30,000 sq ft licensed pharmacy and distribution center in Florida and can process over 150,000 prescriptions per day [7][10]. - The proprietary technology, PerfectOS, enables efficient digital prescription intake and real-time inventory management, enhancing operational efficiency [10][11]. Future Outlook - The partnership is viewed as a critical step in transforming access to modern healthcare and expanding Hydreight's product lineup [8]. - The VSDHOne platform, developed in partnership with Victory Square Technologies, aims to simplify the entry for companies into the online healthcare space, further supporting Hydreight's growth strategy [15].

Core Insights - Hydreight Technologies Inc. reported a strong financial performance in Q2 2025, achieving a 31% year-over-year increase in GAAP revenue to $5.38 million and a topline revenue of $7.35 million, also up 31% compared to Q2 2024 [5][7] - The company has focused on expanding its modular VSDHOne platform, allowing customers to adopt services incrementally, and has prioritized strategic acquisitions to enhance margins and growth [1][3] - Hydreight has successfully entered new verticals such as genetic testing, anti-aging, and mental wellness, contributing to its growth strategy [3][5] Financial Performance - Q2 2025 GAAP revenue was $5.38 million, a 31% increase from Q2 2024, while topline revenue reached $7.35 million, also reflecting a 31% growth [5][7] - For the first six months of 2025, GAAP revenue totaled $9.92 million, up 33% year-over-year, with topline revenue at $13.88 million, also a 33% increase [5][7] - The company reported a gross margin of $1.93 million in Q2 2025, up from $1.56 million in Q2 2024, and an Adjusted EBITDA of $182K, indicating continued operational improvement [5][7] Strategic Initiatives - Hydreight has signed a binding letter of intent to acquire a 5% equity stake in Perfect Scripts, LLC, with an option to increase to 40%, establishing a strategic partnership [5][6] - The company has launched a personalized genetic testing and wellness solution on its VSDHOne platform, expanding its service offerings [6][5] - Hydreight is actively participating in investor conferences to enhance its visibility and attract new investors, with multiple events scheduled throughout 2025 [15][16] User Growth and Market Expansion - The company experienced approximately 77% growth in new nurse signups and a 48% increase in pharmacy orders compared to Q2 2024 [5][7] - The internal metrics for VSDHOne SKU orders indicated a strong demand, with approximately 42,829 pharmacy SKU orders received within the first 60 days of a targeted period [5][7] - Hydreight's platform has hosted over 3,000 nurses and 200 doctors, facilitating flexible at-home medical services across all 50 states in the U.S. [18][19]

Core Viewpoint - Hydreight Technologies Inc. has announced a private placement offering of up to C$10,000,000 in unsecured convertible debentures to support its digital healthcare solutions business [1][6] Group 1: Offering Details - The company has granted Canaccord Genuity Corp. an option to increase the offering size by up to C$1,500,000 [2] - The debentures will mature 36 months from issuance and are convertible into common shares at a price of C$4.06 per share [3] - The offering is expected to close around September 4, 2025, pending regulatory approvals [6] Group 2: Financial Terms - The debentures will bear a fixed interest rate of 9.0% per annum, payable semi-annually [5] - The company will pay a cash commission of 6.0% to the lead agent and issue compensation warrants equal to 6.0% of the number of shares issuable upon conversion [7] Group 3: Company Overview - Hydreight Technologies Inc. is building a large mobile clinic network in the U.S., with over 2,500 nurses and 100 doctors across 50 states [10] - The company's platform includes integrated tools for healthcare professionals to provide services directly to patients [10]

Core Insights - Hydreight Technologies Inc. has reported record-breaking growth in orders for its VSDHOne platform, with July orders significantly exceeding projections and August tracking ahead of schedule towards a goal of 1.3 million total orders for 2025 [2][4] - The partnership with Perfect Scripts and the introduction of 503B compounding capabilities are expected to enhance the scalability, efficiency, and reach of the VSDHOne platform [4][7] - The launch of Hydreight Marketing Solutions aims to drive client growth and increase order volume across the VSDHOne network by providing marketing services tailored for healthcare providers [8][9] Order Growth - VSDHOne platform achieved approximately 7,187 SKU orders in June 2025, surpassing the internal forecast of 7,000–10,000 SKU orders [6] - In July 2025, the platform achieved approximately 35,642 SKU orders, over three times the internal forecast of around 10,000 SKU orders [6] - The internal forecast for August 2025 aims for approximately 55,000 SKU orders [6] Technology and Integration - Hydreight is enhancing the VSDHOne technology platform into a fully modular architecture, allowing businesses to adopt only the necessary components for order generation [3] - Perfect Scripts' technology integrates directly with VSDHOne, automating prescription processing and significantly reducing fulfillment times [7] - The 503B compounding capability allows Hydreight to manufacture and ship high-demand medications at scale, overcoming the limitations of traditional compounding methods [7] Marketing Solutions - Hydreight Marketing Solutions will provide data-driven campaigns and patient acquisition strategies specifically for healthcare providers on the VSDHOne platform [8] - The initiative is expected to drive significant growth, as successful marketing at the client level translates to higher patient volumes and order growth across the network [9] - The goal is to empower partners to market effectively, increasing patient engagement and revenue for all involved [9] Corporate Update - Gabi Kabazo has resigned as a director effective August 8, 2025, to focus on other professional commitments [10] - Hydreight Technologies Inc. has been recognized as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ [11]

Core Insights - Hydreight Technologies Inc. has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference, highlighting its role in the evolving healthcare landscape [1][2] - The company is recognized for its rapid revenue growth and national expansion strategy, with a focus on mobile, on-demand medical services across the U.S. [3][4] Company Overview - Hydreight is building one of the largest mobile clinic networks in the United States, with a proprietary platform that includes over 2500 nurses and 100 doctors across all 50 states [6] - The platform offers integrated tools for healthcare professionals to provide services directly to patients, enhancing compliance and convenience [6] Recent Developments - The company reported a 34% year-over-year revenue growth in Q1, indicating strong financial performance [5] - Hydreight is launching the VSDHOne platform, which simplifies the entry for companies into the online healthcare space, allowing for quick compliance and service launch [7] Leadership Engagement - CEO Shane Madden and Board Chair Shafin Diamond Tejani will represent Hydreight at the conference, engaging with investors to discuss growth and future offerings [3][4]